# A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

> **NCT02567695** · PHASE1 · COMPLETED · sponsor: **Global Blood Therapeutics** · enrollment: 26 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT440

## Key facts

- **NCT ID:** NCT02567695
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567695, "A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02567695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*